Summit Therapeutics Inc. (SMMT) Financial Statements
Free cash flow over the same period: -$459.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SMMTSummit Therapeutics Inc.Follow SMMT — free
—
Price chart with a free account
- Market cap
- 12.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 53.3 | 85.4 | 52.0 | 59.5 | 150.8 | 537.7 | 568.7 | |
| Operating income | -53.2 | -86.2 | -72.1 | -609.7 | -226.0 | — | — | |
| Pre-tax income | -52.9 | -88.6 | -78.8 | -614.9 | -221.3 | -1,079.6 | -856.1 | |
| Income tax | -0.2 | 0.0 | — | 0.0 | 0.0 | 0.0 | — | |
| Net income | -52.7 | -88.6 | -78.8 | -614.9 | -221.3 | -1,079.6 | -856.1 | |
| Diluted EPS ($) | -0.76 | -0.67 | -0.41 | -0.99 | -0.31 | -1.44 | -1.11 | |
| Diluted shares (mn) | 69.5 | 131.7 | 193.3 | 619.6 | 718.5 | 747.7 | — |
USD millions · SEC XBRL
Summit Therapeutics Inc. — questions
- What is Summit Therapeutics Inc.'s net income?
- -$856.1M over the twelve months to 2026-06-30.
- What is Summit Therapeutics Inc.'s free cash flow?
- -$459.8M over the twelve months to 2026-06-30.
- What are Summit Therapeutics Inc.'s diluted earnings per share?
- $-1.11 over the twelve months to 2026-06-30.
Every figure on this page comes from Summit Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.